The invention provides derivatives of cyclopamine having the following formula: ##STR00001##

Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.

Provided are methods of identifying MYC-Driven and/or lipogenesis-dependent neoplasms. Also provided are methods of treating the MYC-Driven neoplasms and methods of treating lipogenesis-dependent neoplasms. Methods of identifying therapeutic agents that are effective against MYC-driven neoplasms are also provided.

Provided are methods of identifying MYC-Driven and/or lipogenesis-dependent neoplasms. Also provided are methods of treating the MYC-Driven neoplasms and methods of treating lipogenesis-dependent neoplasms. Methods of identifying therapeutic agents that are effective against MYC-driven neoplasms are also provided.

A micro-environment bioreaction aggregate (MEBA) is formed by combining a non-digestible carrier system with redox potential (E.sub.h) regulating compounds. The bioreaction aggregate is introduced into a microbial environment, such as soil, hydroponic systems, or gastrointestinal tracts of animals or humans. Said MEBA regulates the E.sub.h of the microbial microhabitat and its surroundings, thereby providing numerous benefits towards the prevention and treatment of diseases and dysbiosis.

A micro-environment bioreaction aggregate (MEBA) is formed by combining a non-digestible carrier system with redox potential (E.sub.h) regulating compounds. The bioreaction aggregate is introduced into a microbial environment, such as soil, hydroponic systems, or gastrointestinal tracts of animals or humans. Said MEBA regulates the E.sub.h of the microbial microhabitat and its surroundings, thereby providing numerous benefits towards the prevention and treatment of diseases and dysbiosis.

There are provided, inter alia, methods of treatment of Zika virus infection.

There are provided, inter alia, methods of treatment of Zika virus infection.

The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune the properties of the compound within the body such that the compound more selectively distributes to tumors and is, or becomes active in the cytosol.

The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune the properties of the compound within the body such that the compound more selectively distributes to tumors and is, or becomes active in the cytosol.